Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for Elliot Sigal. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at Elliot Sigal har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:ONCE / Spark Therapeutics, Inc. | Director | 0 |
US:MJN / Mead Johnson Nutrition Co. | Director | 0 |
US:BMY / Bristol-Myers Squibb Company | EVP, CSO & President R&D, Director | 25 000 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av Elliot Sigal. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av Elliot Sigal som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −25 786 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −17 203 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −6 000 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −4 000 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (Right to Buy) |
D - Sale to Issuer | −4 000 | 0 | −100,00 | ||||
2019-12-17 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
U - Other | −14 214 | 0 | −100,00 | 114,50 | −1 627 503 | ||
2019-06-03 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | −1 500 | 0 | −100,00 | ||||
2019-06-03 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
M - Exercise | 1 500 | 14 214 | 11,80 | ||||
2018-05-31 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Restricted Stock Units |
M - Exercise | −1 500 | 0 | −100,00 | ||||
2018-05-31 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
M - Exercise | 1 500 | 12 714 | 13,38 | ||||
2018-05-31 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 4 000 | 4 000 | |||||
2018-05-31 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Restricted Stock Units |
A - Award | 1 500 | 1 500 | |||||
2018-04-16 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
S - Sale | −29 | 11 214 | −0,26 | 72,43 | −2 100 | 812 230 | |
2018-04-16 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
P - Purchase | 29 | 11 243 | 0,26 | 90,75 | 2 632 | 1 020 302 | |
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Units |
D - Sale to Issuer | −1 709 | 0 | −100,00 | 90,00 | −153 810 | ||
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
D - Sale to Issuer | −5 180 | 0 | −100,00 | 90,00 | −466 200 | ||
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
D - Sale to Issuer | −5 180 | 0 | −100,00 | 90,00 | −466 200 | ||
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
D - Sale to Issuer | −2 590 | 0 | −100,00 | 90,00 | −233 100 | ||
2017-06-15 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
D - Sale to Issuer | −13 721 | 0 | −100,00 | 90,00 | −1 234 890 | ||
2017-06-02 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Restricted Stock Units |
A - Award | 1 500 | 1 500 | |||||
2017-06-02 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 4 000 | 4 000 | |||||
2017-03-02 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −2 373 | 0 | −100,00 | ||||
2017-03-02 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 2 373 | 13 721 | 20,91 | ||||
2017-03-02 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
A - Award | 1 709 | 1 709 | |||||
2016-06-03 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Stock Option (right to buy) |
A - Award | 6 000 | 6 000 | |||||
2016-03-01 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | 2 373 | 2 373 | |||||
2016-03-01 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −1 678 | 0 | −100,00 | ||||
2016-03-01 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 1 678 | 11 348 | 17,35 | ||||
2015-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −2 146 | 0 | −100,00 | ||||
2015-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 2 146 | 9 670 | 28,52 | ||||
2015-02-27 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
A - Award | 1 678 | 1 678 | |||||
2015-02-06 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Series B Preferred Stock |
C - Conversion | −31 559 | 0 | −100,00 | ||||
2015-02-06 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Series B Preferred Stock |
A - Award | 503 | 31 559 | 1,62 | ||||
2015-02-06 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
P - Purchase | 5 000 | 11 214 | 80,46 | 23,00 | 115 000 | 257 922 | |
2015-02-06 |
|
4 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
C - Conversion | 31 559 | 31 559 | |||||
2015-01-29 | 3 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
12 428 | ||||||||
2015-01-29 | 3 | ONCE |
Spark Therapeutics, Inc.
Common Stock |
12 428 | ||||||||
2014-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
A - Award | 2 146 | 2 146 | |||||
2014-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −1 876 | 0 | −100,00 | ||||
2014-03-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 1 876 | 7 524 | 33,22 | ||||
2013-06-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −98 875 | 25 000 | −79,82 | ||||
2013-06-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −83 647 | 148 221 | −36,08 | 48,18 | −4 030 112 | 7 141 288 | |
2013-06-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 98 875 | 231 868 | 74,35 | 27,01 | 2 670 614 | 6 262 755 | |
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −50 000 | 0 | −100,00 | ||||
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −120 625 | 123 875 | −49,34 | ||||
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −143 521 | 132 993 | −51,90 | 47,23 | −6 778 497 | 6 281 259 | |
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 50 000 | 276 514 | 22,07 | 24,74 | 1 237 000 | 6 840 956 | |
2013-05-31 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 120 625 | 226 514 | 113,92 | 27,01 | 3 258 081 | 6 118 143 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −202 405 | 50 000 | −80,19 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −103 500 | 0 | −100,00 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −459 | 9 091 | −4,81 | 39,65 | −18 199 | 360 458 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −919 | 18 180 | −4,81 | 39,65 | −36 438 | 720 837 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −919 | 18 180 | −4,81 | 39,65 | −36 438 | 720 837 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −175 143 | 105 889 | −62,32 | 39,61 | −6 937 414 | 4 194 263 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −90 234 | 281 032 | −24,30 | 39,61 | −3 574 169 | 11 131 678 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −88 132 | 371 266 | −19,18 | 39,63 | −3 492 671 | 14 713 272 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 103 500 | 459 398 | 29,08 | 25,45 | 2 634 075 | 11 691 679 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 202 405 | 355 898 | 131,87 | 24,74 | 5 007 500 | 8 804 917 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −36 503 | 252 405 | −12,63 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −11 092 | 288 908 | −3,70 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −25 795 | 0 | −100,00 | ||||
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −9 157 | 9 550 | −48,95 | 39,97 | −366 005 | 381 714 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −18 313 | 19 099 | −48,95 | 39,97 | −731 971 | 763 387 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −18 313 | 19 099 | −48,95 | 39,97 | −731 971 | 763 387 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −41 868 | 153 493 | −21,43 | 39,92 | −1 671 371 | 6 127 441 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −31 594 | 195 361 | −13,92 | 39,90 | −1 260 601 | 7 794 904 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −21 856 | 226 955 | −8,78 | 39,90 | −872 054 | 9 055 504 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −9 600 | 248 811 | −3,72 | 40,00 | −384 000 | 9 952 440 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 11 092 | 258 411 | 4,48 | 24,74 | 274 416 | 6 393 088 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 25 795 | 247 319 | 11,64 | 22,73 | 586 320 | 5 621 561 | |
2013-05-01 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 36 503 | 221 524 | 19,73 | 24,74 | 903 084 | 5 480 504 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
A - Award | 29 630 | 29 630 | |||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 845 | 22 011 | 3,99 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 21 166 | 21 166 | |||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 2 466 | 64 243 | 3,99 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 27 866 | 61 777 | 82,17 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
M - Exercise | −99 812 | 0 | −100,00 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 3 832 | 99 812 | 3,99 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 29 007 | 95 980 | 43,31 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −8 801 | 26 406 | −25,00 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −12 062 | 35 491 | −25,37 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −11 715 | 47 553 | −19,77 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −51 754 | 185 021 | −21,86 | 37,53 | −1 942 328 | 6 943 838 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −9 343 | 236 775 | −3,80 | 37,53 | −350 643 | 8 886 166 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −8 748 | 246 118 | −3,43 | 37,53 | −328 312 | 9 236 809 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −5 194 | 254 866 | −2,00 | 37,53 | −194 931 | 9 565 121 | |
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 1 216 | 260 060 | 0,47 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 5 156 | 258 844 | 2,03 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 5 957 | 253 688 | 2,40 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 8 801 | 247 731 | 3,68 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 11 715 | 238 930 | 5,16 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 12 062 | 227 215 | 5,61 | ||||
2013-03-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 99 812 | 215 153 | 86,54 | ||||
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −7 453 | 0 | −100,00 | ||||
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −3 865 | 115 341 | −3,24 | 36,94 | −142 773 | 4 260 697 | |
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 7 453 | 119 206 | 6,67 | ||||
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −46 365 | 46 367 | −50,00 | ||||
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −24 041 | 111 753 | −17,70 | 37,15 | −893 123 | 4 151 624 | |
2013-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 46 365 | 135 794 | 51,85 | ||||
2013-03-04 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
M - Exercise | −1 789 | 0 | −100,00 | ||||
2013-03-04 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 1 789 | 5 648 | 46,36 | ||||
2013-03-04 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Unit (RSU) |
A - Award | 1 876 | 1 876 | |||||
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Option (right to buy) |
M - Exercise | −48 333 | 0 | −100,00 | ||||
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −70 000 | 25 795 | −73,07 | ||||
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Executive Option (right to buy) |
M - Exercise | −147 749 | 0 | −100,00 | ||||
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −224 705 | 89 429 | −71,53 | 36,79 | −8 266 897 | 3 290 093 | |
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 48 333 | 314 134 | 18,18 | 28,11 | 1 358 641 | 8 830 307 | |
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 70 000 | 265 801 | 35,75 | 22,73 | 1 591 100 | 6 041 657 | |
2013-02-11 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 147 749 | 195 801 | 307,48 | 17,51 | 2 587 085 | 3 428 476 | |
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −62 903 | 37 412 | −62,71 | 33,00 | −2 075 799 | 1 234 596 | |
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −62 903 | 37 412 | −62,71 | 33,00 | −2 075 799 | 1 234 596 | |
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
S - Sale | −31 451 | 18 707 | −62,70 | 33,00 | −1 037 883 | 617 331 | |
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
G - Gift | 100 315 | 100 315 | |||||
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
G - Gift | 100 315 | 100 315 | |||||
2012-12-13 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
G - Gift | −200 630 | 50 158 | −80,00 | ||||
2012-12-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
G - Gift | 5 180 | 5 180 | |||||
2012-12-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
G - Gift | 5 180 | 5 180 | |||||
2012-12-03 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
G - Gift | −10 360 | 2 590 | −80,00 | ||||
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
J - Other | −4 | 0 | −100,00 | 71,35 | −282 | ||
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 4 | 71,35 | 282 | 282 | ||
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
J - Other | −1 083 | 0 | −100,00 | 74,19 | −80 361 | ||
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 083 | 0,37 | 68,11 | 275 | 73 779 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 079 | 0,38 | 69,04 | 282 | 74 508 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 5 | 1 075 | 0,45 | 58,33 | 279 | 62 711 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 070 | 0,36 | 62,30 | 238 | 66 681 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 067 | 0,40 | 56,25 | 240 | 59 991 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 5 | 1 062 | 0,45 | 50,53 | 241 | 53 675 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 5 | 1 057 | 0,43 | 52,90 | 241 | 55 940 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 4 | 1 053 | 0,42 | 46,81 | 208 | 49 287 | |
2012-09-14 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
P - Purchase | 9 | 1 048 | 0,84 | 44,58 | 389 | 46 741 | |
2012-09-07 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
J - Other | −12 950 | 16 809 | −43,52 | ||||
2012-09-07 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | −250 788 | 298 840 | −45,63 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −6 875 | 0 | −100,00 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 1 457 | 33 911 | 4,49 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 32 454 | 32 454 | |||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
M - Exercise | −78 955 | 66 973 | −54,11 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
J - Other | 2 879 | 145 928 | 2,01 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 28 152 | 143 049 | 24,50 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Performance Shares |
A - Award | 33 783 | 114 897 | 41,65 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
A - Award | 35 207 | 35 207 | |||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −36 597 | 298 840 | −10,91 | 32,33 | −1 183 181 | 9 661 497 | |
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −3 187 | 335 437 | −0,94 | 32,33 | −103 036 | 10 844 678 | |
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 6 875 | 338 624 | 2,07 | ||||
2012-03-08 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 78 955 | 331 749 | 31,23 | ||||
2012-03-06 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Units |
M - Exercise | −1 699 | 1 789 | −48,71 | 78,26 | −132 964 | 140 007 | |
2012-03-06 |
|
4 | MJN |
Mead Johnson Nutrition Co
Restricted Stock Units |
A - Award | 1 789 | 3 488 | 105,30 | ||||
2012-03-06 |
|
4 | MJN |
Mead Johnson Nutrition Co
Common Stock |
M - Exercise | 1 699 | 16 809 | 11,24 | 78,26 | 132 964 | 1 315 472 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −7 453 | 7 453 | −50,00 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −3 455 | 252 794 | −1,35 | 32,59 | −112 598 | 8 238 556 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 7 453 | 256 249 | 3,00 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −46 365 | 92 732 | −33,33 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −21 491 | 248 796 | −7,95 | 32,59 | −700 392 | 8 108 262 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 46 365 | 270 287 | 20,71 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −12 062 | 59 268 | −16,91 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −7 383 | 223 922 | −3,19 | 32,59 | −240 612 | 7 297 618 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 3 866 | 231 305 | 1,70 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 12 062 | 227 439 | 5,60 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Market Share Units |
M - Exercise | −11 714 | 71 330 | −14,11 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −5 412 | 215 377 | −2,45 | 32,64 | −176 648 | 7 029 905 | |
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
J - Other | 3 173 | 220 789 | 1,46 | ||||
2012-03-05 |
|
4 | BMY |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
M - Exercise | 11 714 | 217 616 | 5,69 | ||||
2011-12-29 |
|
4/A | BMY |
BRISTOL MYERS SQUIBB CO
Restricted Stock Units |
M - Exercise | −6 875 | 13 750 | −33,33 | ||||
2009-03-12 | 3 | MJN |
Mead Johnson Nutrition Co
Common Stock |
5 000 | ||||||||
2003-08-04 |
|
4 | (BMY) |
BRISTOL MYERS SQUIBB CO
Common Stock, $0.10 par value |
F - Taxes | −1 219 | 75 024 | −1,60 |